Results 101 to 110 of about 7,331 (198)
Journal of Anaesthesiology Clinical Pharmacology, 2013 Abhijit S Nair, T V S Gopal
openaire +3 more sources
Evaluation of Clinical outcomes of Generic versus Reference Ivabradine in Heart Failure Patients
Archives of Pharmaceutical Sciences Ain Shams University, 2020 Economic benefits associated with usage of generic drugs have been suggested to increase patients’ adherence to their medications and to improve patients’ health outcomes.
Hadeer Eid +5 more
doaj
Chronotropic effect of ivabradine and ryanodine.
, 2014 Panel A: Series of APs were recorded from a patch clamped SANC, first perfused in NT, then in 3 µM ivabradine, then back in NT (not shown), and finally in 3 µM ryanodine. Switching times are reported as vertical arrows. Time was allowed for AP parameters
Massimiliano Zaniboni (579796) +2 more
core +1 more source
Arrhythmic effects of Ivabradine in patients with coronary artery disease
, 2009 Objectives: Ivabradine is the first specific heart rate-lowering agent that has completed clinical development for stable angina pectoris. The aim of the present study was to investigate the effects of ivabradine therapy on P-wave duration, dispersion ...
Ramazan Akdemir +5 more
core +1 more source
Inhibitory action of ivabradine on hHCN4 channel
, 2003 Inhibitory action of ivabradine on hHCN4 ...
M. Baruscotti, D. DiFrancesco, A. Bucchi
core
HFrEF pharmacological treatment: ivabradine
, 2018 Ivabradine slows down the heart rate through a blockade of the funny current channels in the sinoatrial node cells. The efficacy of the drug was tested in a large outcome clinical trial in stable chronic heart failure with reduced ejection fraction, in ...
Michel Komajda
core +1 more source
Ivabradine block of If is current dependent
, 2002 Ivabradine block of If is current ...
M. Baruscotti, D. DiFrancesco, A. Bucchi
core
Clinical Implications of Ivabradine in the Contemporary Era
Ivabradine is a recently introduced inhibitor of the If ion channel, which exhibits the capacity to reduce heart rate while preserving hemodynamic stability.
Teruhiko Imamura
core +1 more source